
Media
Media
Our latest announcements
Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV
10/10/2025
Hansa Biopharma to host Q3 2025 interim results conference call
08/10/2025
Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025
07/10/2025
Hansa Biopharma publishes disclosure document for admission to trading of shares on Nasdaq Stockholm
Regulatory press release
02/10/2025
Media articles
Insights
The Power of Hope: Redefining Treatment Decisions for Highly Sensitized Kidney Patients
07/08/2025
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024